Colorectal Cancer Clinical Trial
— PrehabVsERASOfficial title:
Comparison of Preoperative Multimodal Preparation Program (Prehabilitation) With Enhanced Recovery Program for Elective Colorectal Cancer Surgery.
Verified date | March 2020 |
Source | St. Borbala Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Elective surgery is the most effective treatment option for colorectal cancer, however it has
been recognized to be associated with high morbidity and mortality risks.
ERAS (Enhanced Recovery After Surgery) is a preoperative multimodality treatment package,
which has been well investigated and proved to be effective in reducing early postoperative
morbidity, mortality, length of hospital stay and hospital costs, as well. Still, a good
proportion of patients are not suitable for ERAS program, mainly based on lack of compliance
and the impaired physical function before surgery.
Prehabilitation Program is a recently introduced trimodal preoperative preparation (training)
program, which addresses improvement of physical, mental and nutritional status of the high
risk elective surgery patients.
This study aims to investigate the benefit of all efforts of a 4-6-week preoperative
preparation program (Prehabilitation) being added to an established ERAS protocol.
Status | Completed |
Enrollment | 184 |
Est. completion date | November 1, 2019 |
Est. primary completion date | November 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patient with histologically proven primary colorectal adenocarcinoma - any stage of colorectal cancer - elective operation - curative intention - informed consent signed by patient Exclusion Criteria: - emergency operation - palliative operation - non-colorectal, second malignancy - pregnancy - patient not giving consent |
Country | Name | City | State |
---|---|---|---|
Hungary | Department of Surgery, St. Borbala Hospital | Tatabánya |
Lead Sponsor | Collaborator |
---|---|
St. Borbala Hospital | Semmelweis University, St. Borbala Hospital, Department of Surgery |
Hungary,
Bánky B, Lakatos M, Varga K, Hansági E, Horváth É, Járay G. [Enhanced Recovery Program in colorectal surgery]. Magy Seb. 2018 Mar;71(1):3-11. doi: 10.1556/1046.71.2018.1.1. Hungarian. — View Citation
Bousquet-Dion G, Awasthi R, Loiselle SÈ, Minnella EM, Agnihotram RV, Bergdahl A, Carli F, Scheede-Bergdahl C. Evaluation of supervised multimodal prehabilitation programme in cancer patients undergoing colorectal resection: a randomized control trial. Acta Oncol. 2018 Jun;57(6):849-859. doi: 10.1080/0284186X.2017.1423180. Epub 2018 Jan 12. — View Citation
Carli F, Silver JK, Feldman LS, McKee A, Gilman S, Gillis C, Scheede-Bergdahl C, Gamsa A, Stout N, Hirsch B. Surgical Prehabilitation in Patients with Cancer: State-of-the-Science and Recommendations for Future Research from a Panel of Subject Matter Experts. Phys Med Rehabil Clin N Am. 2017 Feb;28(1):49-64. doi: 10.1016/j.pmr.2016.09.002. Review. — View Citation
Chen BP, Awasthi R, Sweet SN, Minnella EM, Bergdahl A, Santa Mina D, Carli F, Scheede-Bergdahl C. Four-week prehabilitation program is sufficient to modify exercise behaviors and improve preoperative functional walking capacity in patients with colorectal cancer. Support Care Cancer. 2017 Jan;25(1):33-40. Epub 2016 Aug 18. — View Citation
Souwer ETD, Bastiaannet E, de Bruijn S, Breugom AJ, van den Bos F, Portielje JEA, Dekker JWT. Comprehensive multidisciplinary care program for elderly colorectal cancer patients: "From prehabilitation to independence". Eur J Surg Oncol. 2018 Dec;44(12):1894-1900. doi: 10.1016/j.ejso.2018.08.028. Epub 2018 Sep 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Length of hospital stay | Postoperative length of hospital stay in days. | within 45 days | |
Primary | Number of days spent on ICU (Intensive care unit). | Number of days observed on ICU right after operation. | within 45 days postoperative | |
Primary | Morbidity (early) classified after Clavien-Dindo. | 7-day morbidity will be detailed assessed. Grade 3 or above morbidity rate will be assessed. | 7 days (until 8th postoperative day) postoperative | |
Primary | Morbidity (long term) classified after Clavien-Dindo. | 30-day morbidity will be detailed assessed. Grade 3 or above morbidity rate will be assessed. | 30 days (until 31st postoperative day) | |
Primary | 30-day mortality | 30-day mortality of each patient will be recorded. | 30 days postoperative | |
Primary | 90-day mortality | 90-day mortality of each patient will be recorded. | 90 days postoperative | |
Primary | Change in preoperative functional status - 6MWD by operation | 6MWD (6-minute walking distance test) | Measured points: 4 weeks before surgery, on day of hospital admission | |
Primary | Change in postoperative functional status - 6MWD by the end of rehabilitation | 6MWD (6-minute walking distance test) | Measured points: 4 weeks before surgery, 8 weeks after operation | |
Primary | Change in preoperative functional status - FVC by operation | FVC (forced vital capacity) will be measured. | Measured points: 4 weeks before surgery, on day of hospital admission | |
Primary | Change in preoperative functional status - FVC by the end of rehabilitation | FVC (forced vital capacity) will be measured. | Measured points: 4 weeks before surgery, 8 weeks after operation | |
Secondary | Delay in beginning of adjuvant oncotherapy (chemotherapy, radiotherapy). | Sufficient recovery time until fitness of adjuvant chemo/radiotherapy will be recorded. | within 8 weeks, if adjuvant oncotherapy is needed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |